Dr Ira Kirschenbaum Contributions to the Orthopedic Industry

Dr. Ira Kirschenbaum MD. is a distinguished orthopedic surgeon who has contributed significantly to the orthopedic industry. Dr. Kirschenbaum serves at the helm of the orthopedic department at Bronxcare Health System as Chairman. He received his training in medicine from Brown University, the prestigious Albert Einstein College of Medicine and Rotham Institute. Dr. Ira Kirschenbaum is also a businessman who has helped establish several firms in the healthcare industry. He co-founded Medscape that was later acquired by GQ and WebMD respectively.

Dr. Ira Kirschenbaum has achieved a lot in the orthopedic industry. Some of Dr. Kirschenbaum accomplishment in the sector includes helping design multiple joint replacements systems that have significantly contributed to increasing efficiency, reduce pain and save on the cost of joint replacement surgeries. Dr. Kirschenbaum besides has traveled far and wide to deliver lectures at top world universities on topics related to joint replacement surgeries. Dr. Ira Kirshchenabaum other contribution to the industry is that he has authored and published many publications on joint replacement, orthopedic surgery and technological advancements in the industry among other things.

Dr. Ira Kirschenbaum is an experienced orthopedic surgeon with decades of expertise in the industry has successfully performed thousands of joint replacement surgeries to patients not only in the US but globally. Dr. Ira Kirschenbaum area of specialization is knee, shoulder and hip joints including adult reconstructive surgeries. Dr. Ira Kirschenbaum work and contributions to the industry have not gone unnoticed. In recognition of his efforts in the sector, Dr. Ira has received numerous awards for innovation, ethics and providing quality care.

Dr. Ira Kirschenbaum has previously served at Kaiser Permanente System and is still serving at senior positions at both Swiftpath Program and DTC Healthcom. Dr. Ira Kirschenbaum in an interview said that one habit that makes him more productive is by continuously focusing on building work relationships with his colleagues in the department he serves in and frequently conducting focused meetings with the management.

Read Dr. Ira’s reviews here https://www.vitals.com/doctors/Dr_Ira_Kirschenbaum.html

Unsure If You Should Take The “Basis” Supplement? Read on to Find Out Why It Works

Anyone who has wondered about what the supplement Basis is all about is not alone. It comes from Elysium Health, a consumer health company co-founded by Dr. Leonard Guarente. Long before he co-founded Elysium Health, Guarente conducted significant research on the molecular and genetic causes of aging. In addition to serving as chief scientist of Elysium, Guarente is also  the director of the Paul F. Glenn Center for Biology of Aging Research at MIT.

Elysium works with a network of  world-class scientists and clinicians from leading academic institutions including Harvard, Yale, and Stanford. These scientists guide the direction of the company and its research.

Basis works by increasing levels of a coenzyme in the body known as NAD+. This is a very important coenzyme as it relates directly to our cellular health overall. NAD+ levels decline naturally in our body as we age. In a clinical trial, Basis increased NAD+ levels safely and sustainably by an average of 40 percent.

It is easy to purchase individual bottles of Basis or a subscription plan via the Elysium Health website. Take a look at some of the subscription levels from the company’s website:

  • Month-to-Month: $50
  • Six Months: $270 ($45 per month)
  • One Year: $480 ($40 per month)

The longer your subscription, the more money you’ll save. The six-month plan is the most popular at the moment. You can also purchase an individual bottle for $60.



Omar Boraie Contribution In Development Of Cancer Treatment


In the recent past, precision medicine and genomic science have revolutionized how medical professionals carry out the cancer diagnosis process. Today, it is possible for physicians to scrutinize tumors on a genetic level. The move has revolutionized cancer treatment. It has become much better that it was in the past and individuals who have cancer can get specialized therapies according to how cancer has affected their body tissues. It has made the treatment to be more efficient and reliable.

Although various cancer centers countrywide have adopted the technology of gene structuring on tumors research, the Rutgers Cancer Institute was the first in the country to use genomic sequencing as precision medicine for cancer treatment and patient care. The process of genomic sequencing has been playing a critical role in coming up with an efficient manner to handle cancer cases and come up with specialized therapies for different individuals.

According to an article published on NJ Biz, a facility named after Omar Boraie has been set aside at Rutgers Cancer Institute to provide a better environment for precision medicine research carried out in the Institute. The facility was named after Oncologist and Brunswick developer Omar Boraie who contributed $1.5 million in support of the Project. The Chair is expected to come up with solutions for cancer treatment through precision medicine. The project is supposed to cost $3 million where the contributor of the other half has preferred to remain anonymous.

According to a report by Patch.com, the Chair of Omar Boraie Genomic Science Dr. Ganesan, Cancer is not a single disease and treating it by considering just the organ it has affected is a wrong way to go about the treatment process. Using Genomic analyses, the treatment becomes more efficient since it is fast and show all the feature of the disease. The process also helps to tailor therapies for each patient who visit the cancer treatment center.


Omar Boraie is has played a key role in cancer research and treatment. He has been a keen player coming up with ways of treating cancer; he has funded research projects and worked with cancer researchers to develop precision medicine approach for cancer treatment.

Reference: http://www.nytimes.com/2005/03/06/realestate/at-two-extremes-of-a-housing-market.html